Non-antibiotic versus Antibiotic Prophylaxis for Recurrent Urinary Tract Infections

Submission date	Recruitment status No longer recruiting	Prospectively registered		
12/09/2005		☐ Protocol		
Registration date 12/09/2005	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited 10/04/2014	Condition category Urological and Genital Diseases	Individual participant data		

Plain English summary of protocol

Background and study aims

Urinary tract infections (UTIs) are very common infections in women. For women with UTIs which happen more than twice a year, low dose antibiotic prophylaxis (preventative treatment) for several months can be recommended. However, this can lead to resistance of not only the bacteria responsible for the UTI but also of all the natural bacterial found on/in a healthy person. Previous studies have demonstrated that prophylaxis with non-antibiotic compounds (lactobacilli oral therapy) compared with a dummy treatment may lead to a lower number of new UTI episodes. Cranberry juice, compared with a dummy treatment, has also resulted in fewer UTIs in women. This study aims to compare these forms of non-antibiotic prophylaxis to antibiotic prophylaxis.

Who can participate?

Women who have an indication for prophylaxis of recurrent UTIs.

What does the study involve?

Participants will be randomly allocated to one of four treatments. In study A, 280 premenopausal women will receive either cranberry capsules or standardized antibiotic treatment. In study B, 280 postmenopausal women will receive either lactobacilli oral therapy or standardized antibiotic treatment.

Each month, during 15 months, all patients have to fill in a short questionnaire and to collect urine, faeces and a vaginal swab. At the beginning of the study and after 6,12 and 15 months they will have to fill in a longer questionnaire about quality of life.

What are the possible benefits and risks of participating? Not provided.

Where is the study run from? Academic Medical Center, Amsterdam, the Netherlands.

When is the study starting and how long is it expected to run for? September 2005 to September 2009

Who is funding the study?
The work was supported by the Netherlands Organization for Health Research and Development

Who is the main contact? NAPRUTI@amc.uva.nl

Contact information

Type(s)

Scientific

Contact name

Dr Mariëlle Beerepoot

Contact details

Academic Medical Centre
Dep Infectieziekten, tropische geneeskunde en AIDS
P.O. Box 22660
Amsterdam
Netherlands
1105 AZ
+31 (0)20 5667921
M.A.Beerepoot@amc.uva.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Project 6200.0017 (ZonMw); NTR79

Study information

Scientific Title

Acronym

The NAPRUTI-study.

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

Multicentre, randomised, double blinded, active controlled, parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Urinary tract infections

Interventions

In trial A, 280 pre-menopausal women will receive either cranberry capsules (twice daily 500 mg) or standardised antibiotic treatment (once daily 480 mg trimethoprim-sulfamethoxazole [TMP/SMX]).

In trial B, 280 postmenopausal women will receive either lactobacilli oral therapy (twice daily a capsule with greater than 10^9 Lactobacillus rhamnosus GR-1 and L. reuteri RC-14) or standardised antibiotic treatment (480 mg TMP/SMX).

The double-dummy method is used for blinding. Each patient receives one tablet and two capsules daily, but only one of them (the tablet or the capsules) contains the active substance. All study medication must be taken for the duration of 12 months. During the treatment period and the three months after stopping the treatment (wash-out period), each month patients have to fill in a short questionnaire and collect urine, faeces and a vaginal swab for culturing.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Cranberry capsule, trimethoprim-sulfamethoxazole, lactobacilli oral therapy

Primary outcome measure

- 1. The numbers of recurrences of symptomatic UTI
- 2. Time to first occurrence of antibiotic resistance in urine or faeces

Secondary outcome measures

- 1. Incidence of other infections
- 2. Incidence of asymptomatic bacteriuria events
- 3. Quality of life
- 4. Costs per prevented UTI

Overall study start date

01/09/2005

Completion date

01/09/2009

Eligibility

Key inclusion criteria

- 1. Women aged 18 years or older
- 2. At least three symptomatic urinary tract infections (UTIs), uncomplicated or complicated, in the year preceding study inclusion OR already using any form of prophylaxis to prevent recurrences of urinary tract infections and at least three symptomatic urinary tract infections in the year befort the start of the prophylaxis

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

560

Key exclusion criteria

- 1. Life expectancy less than or equal to one year
- 2. Legally incapable
- 3. A renal transplant in the medical history
- 4. Contraindications for or relevant interactions with trimethoprim-sulfamethoxazole (TMP/SMX)
- 5. Additional exclusion criteria for trial A (pre-menopausal women randomised to either cranberry capsules or TMP/SMX):
- 5.1. Breastfeeding, pregnancy, or pregnancy wish for the next year
- 5.2. Contraindications for or relevant interactions with cranberries

Date of first enrolment

01/09/2005

Date of final enrolment

01/09/2009

Locations

Countries of recruitment

Netherlands

Study participating centre Academic Medical Centre Amsterdam

Netherlands 1105 AZ

Sponsor information

Organisation

Academic Medical Centre (AMC) (The Netherlands)

Sponsor details

P.O. Box 22660 Amsterdam Netherlands 1100 DD

Sponsor type

Hospital/treatment centre

Website

http://www.amc.nl/

ROR

https://ror.org/03t4gr691

Funder(s)

Funder type

Research organisation

Funder Name

The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results of cranberries vs antibiotics	25/07/2011		Yes	No
Results article	results of lactobacilli vs antibiotics	14/05/2012		Yes	No
Results article	results	04/04/2014		Yes	No